Summary
Stryker Corporation reported robust revenue growth in 2011, driven by strong performance across its three key segments: Reconstructive, MedSurg, and Neurotechnology and Spine. The company's strategic acquisitions, particularly the significant Neurovascular division acquisition from Boston Scientific, played a crucial role in expanding its market presence and product portfolio, especially in the neurotechnology space. Despite a challenging economic environment and increased R&D investments, Stryker demonstrated solid operational execution, with notable revenue increases in both domestic and international markets. The company also managed its costs effectively, although certain one-time charges related to restructuring and acquisition integration impacted reported net earnings. Stryker's financial position remains strong, supported by healthy operating cash flow and a well-managed debt structure, allowing for continued investment in innovation and shareholder returns through dividends and share repurchases.
Financial Highlights
52 data points| Revenue | $8.31B |
| Cost of Revenue | $2.81B |
| Gross Profit | $5.50B |
| R&D Expenses | $462.00M |
| SG&A Expenses | $3.15B |
| Operating Expenses | $3.81B |
| Operating Income | $1.69B |
| Interest Expense | $56.00M |
| Net Income | $1.34B |
| EPS (Basic) | $3.48 |
| EPS (Diluted) | $3.45 |
| Shares Outstanding (Basic) | 386.50M |
| Shares Outstanding (Diluted) | 389.50M |
Key Highlights
- 1Stryker Corporation generated $8,307 million in net sales in 2011, a 13.5% increase year-over-year, with constant currency sales growth of 11.1%.
- 2The company completed several strategic acquisitions in 2011, including the significant Neurovascular division from Boston Scientific for $1,450 million, bolstering its Neurotechnology and Spine segment.
- 3The Neurotechnology and Spine segment experienced substantial growth, with net sales increasing by 48.5% (46.4% in constant currency) due to acquisitions.
- 4Operating income for 2011 was $1,686 million, a slight decrease from $1,751 million in 2010, impacted by increased operating expenses including R&D and SG&A.
- 5Net earnings for 2011 were $1,345 million, an increase of 5.7% from 2010, with diluted EPS of $3.45.
- 6The company repurchased 11.8 million shares of common stock in 2011 for a total cost of $622 million, demonstrating a commitment to returning capital to shareholders.
- 7Research, development, and engineering expenses increased by 17.3% in 2011, reflecting a strategic focus on new product development and innovation.